admin

When personal genomics and biotech firm 23andMe was founded in Mountain View, Calif., in 2006, the hype over the genetic tests it offered directly to consumers was immediate and irresistible to many. The company promised that for a nominal fee, it could scan your saliva sample and tell you — based on your genetics — everything from who your ancestors were to what diseases you may be at risk of developing many years down the road. 23andMe raised more than $100 million in capital from such big-name investors as Google and Genentech. Today, the company’s website boasts having close to 500,000 “genotyped consumers.”

So it was a surprise to some observers when, on November 22, the U.S. Food & Drug Administration (FDA) sent a strongly worded letter to 23andMe CEO Anne Wojcicki demanding that the company stop marketing its test, called Personal Genome Service (PGS), until it secures authorization from the agency. The FDA contends that PGS is a medical device being pitched for the diagnosis and prevention of disease, and therefore it must obtain approval under federal law.

The three months of intense focus. The crafting of the perfect pitch. The big presentation on demo day, followed by press mentions and meetings with investors.

And…then what? What comes after the accelerator?

For the entrepreneurs of Rock Health’s Boston Class, which wrapped up in August of 2012, there have been four follow-on fundings, some pilot tests, a pivot and a few long quiet periods. I checked in with the entrepreneurs just over a year after they completed to program to see how they’re all doing now.

The National Institutes of Health is releasing funding opportunities to build a new arsenal of tools and technologies for unlocking the mysteries of the brain. The NIH action is in support of President Obama’s Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative.

The six opportunities announced today were developed in response to high priority areas(PDF – 536KB) identified by the NIH Advisory Committee to the Director’s BRAIN Working Group in September 2013. Awards are expected to be announced in September 2014 and will constitute NIH’s initial investment of $40 million in the initiative.

The Bill & Melinda Gates Foundation just got a physician, big university administrator, and one of the world’s most respected drug developers rolled into one as its new CEO.

Susan Desmond-Hellmann, the chancellor of UC San Francisco since 2009 and the former president of product development at Genentech, has been hired as the new CEO of the Gates Foundation, according to a statement from the foundation. She will start on May 1. UCSF said Sam Hawgood, the dean of the school of medicine, will replace Desmond-Hellmann as interim chancellor.

Combined capabilities provide scientists with access to new and existing immortalized cell lines for use in broad research applications and clinical markets.

ATCC, the premier global biological materials resource and standards organization, and Evercyte GmbH, a proven developer of immortalized human cells, have entered into a strategic partnership to develop and distribute immortalized cell lines that retain key performance characteristics of primary cells. Immortalized primary cell lines enable scientists to have a sufficient supply of physiologically relevant cells for extended studies in biological, medical, pharmaceutical, cosmetic, and toxicological research.

Johns Hopkins University has the sixth-most driven student body in the world, according to data compiled by London-based startup ViewsOnYou.

The website uses three components to match people with a company or employer — energy, interpersonal and intelligence. There are more than 20 metrics that fall into those components, one of which is an individual’s drive.

Startups selected for the DreamIt Health Baltimore accelerator program will get $50,000 in seed funding and access to industry heavyweights like Northrop Grumman Corp.

The defense contractor has signed on as a partner for the new health IT accelerator program, where 10 startups will be selected for the program. The first program runs Jan. 17 through May 9.